Mankind Pharma Share News - Latest Updates, Live News & More

Latest news about Mankind Pharma

Mankind Pharma Launches 'Kindcare Foundation' as Non-Profit Subsidiary Jun 02, 2025

Mankind Pharma has established a new wholly owned subsidiary named 'Kindcare Foundation', a not-for-profit organization aimed at enhancing its corporate social responsibility efforts. This move signifies the company's increased commitment to social welfare and community development. While specific activities are not yet disclosed, the foundation is expected to focus on areas such as healthcare accessibility, disease awareness, and community health initiatives. This development is likely to be viewed positively by investors, employees, communities, and regulators.

Mankind Pharma Reports Mixed Q4 Results, Dolat Capital Adjusts Target Price May 22, 2025

Mankind Pharma Q4 Results: Revenue Surges 27%, Profit Dips 10.7% YoY May 21, 2025

Mankind Pharma Q4 Results: Revenue Growth Expected Amid Profit Concerns May 20, 2025

Mankind Pharma Faces Rs 341.86 Crore Tax Demand, Plans to Appeal May 14, 2025

More news about Mankind Pharma

08May 25

Mankind Pharma Sets Date for Q4 Financial Results Review

Mankind Pharma has scheduled a review of its fourth quarter financial results for May 21, 2023. This announcement signals the company's readiness to disclose its earnings report for the final quarter of the fiscal year. The review will provide insights into the company's financial performance, including revenue figures, profit margins, sales growth, and market share updates.

15Apr 25

Mankind Pharma Unveils Strategic Expansion with New Subsidiaries and Integration Plans

Mankind Pharma has approved several strategic initiatives: establishing a wholly-owned subsidiary in Russia with a $5 million investment to distribute BSV products, creating an Indian subsidiary for CSR activities with Rs. 5 lakh initial investment, and forming a committee to explore integration options for Bharat Serums and Vaccines Limited. These actions aim to expand the company's global footprint and streamline operations, subject to regulatory approvals.

14Apr 25

Mankind Pharma Unveils Major Corporate Restructuring and Global Expansion Strategy

Mankind Pharma has revealed strategic initiatives including potential integration of Bharat Serums and Vaccines, establishment of a Russian subsidiary with $5 million investment for product distribution, and creation of an Indian CSR subsidiary. The company's board approved these plans on April 14, 2025, signaling a new growth phase. The Russian subsidiary will distribute BSV products, while the Indian entity will manage CSR activities with an initial Rs. 5 lakh investment. These moves are subject to various regulatory approvals.

01Apr 25

Mankind Pharma Faces ₹183 Crore Tax Demand Amidst Strong Financial Growth

Mankind Pharma faces an additional tax demand of ₹183 crore ($22 million) from Indian tax authorities. Despite this, the company's financial position remains robust, with significant year-over-year growth in key metrics. Total assets increased by 21.84% to ₹11,417.70 crore, current assets rose by 56.11% to ₹5,490.40 crore, and total equity grew by 23.64% to ₹9,623.80 crore in FY 2024. The tax demand represents 1.60% of the company's total assets, suggesting Mankind Pharma is well-positioned to manage this liability.

01Apr 25

Mankind Pharma Announces NCLT Approval for BSV Pharma-Bharat Serums Merger

Mankind Pharma announced that the National Company Law Tribunal (NCLT) has approved the amalgamation of BSV Pharma with Bharat Serums and Vaccines. This merger in the Indian pharmaceutical industry is expected to combine the strengths and resources of both entities, potentially leading to enhanced operational efficiencies, expanded product portfolios, and strengthened market presence.

29Mar 25

Mankind Pharma Completes Merger of Three Subsidiaries, Adjusts Authorized Share Capital

Mankind Pharma has finalized the amalgamation of three subsidiaries - Shree Jee Laboratory, JPR Labs, and Jaspack Industries - effective March 29, 2025. The merger, approved by NCLT New Delhi, transfers all assets and liabilities to Mankind Pharma. The company's authorized share capital has been revised to ₹421.51 crore. Additionally, NCLT Mumbai has approved the merger of BSV Pharma with Bharat Serums and Vaccines Limited, a material subsidiary of Mankind Pharma.

28Mar 25

Mankind Pharma's Subsidiary Merger Approved by NCLT; Company Faces Tax Assessment Orders

Mankind Pharma's subsidiary Bharat Serums and Vaccines Limited (BSVL) received NCLT approval to merge with BSV Pharma Private Limited, effective May 9, 2022. The merger aims to consolidate operations and improve efficiency. Separately, Mankind Pharma received income tax assessment orders for 2014-15 to 2017-18, with additional tax demands of ₹183.11 crore. The company plans to appeal, asserting the demands are not legally tenable.

21Mar 25

Mankind Pharma Set to Benefit from FTSE All World Index Upgrade

Mankind Pharma has been upgraded in the FTSE All World Index, expected to bring in $16 million (₹133 crore) of foreign investment. This upgrade is likely to increase the company's global visibility and potentially improve stock liquidity. Index funds and ETFs tracking the FTSE All World Index may need to adjust their holdings, possibly leading to automatic buying of Mankind Pharma stock.

12Mar 25

Mankind Pharma Launches Generic Empagliflozin for Diabetes Treatment in India

Mankind Pharma has introduced generic Empagliflozin under three brand names: Empaglyde, Empagreat, and Dynaduo. The medication is available in 10mg tablets priced at ₹5.49 and 25mg tablets at ₹9.90. This launch follows the expiration of Boehringer Ingelheim's patent in India. The move aims to increase accessibility and affordability of diabetes treatment, potentially capturing a significant market share. It aligns with Mankind Pharma's strategy to expand in the chronic diseases segment, particularly diabetes care.

10Mar 25

Mankind Pharma Set to Revolutionize Diabetes Treatment with Affordable Empagliflozin

Mankind Pharma is set to introduce generic versions of Empagliflozin, a crucial diabetes medication, at prices up to 85% lower than current market rates. The company plans to offer the drug at Rs 9-14 per tablet, compared to the current price of Rs 60. This move is part of a broader trend in the Indian pharmaceutical industry to make diabetes treatments more accessible. The launch is expected to significantly impact the diabetes care market in India, potentially improving treatment outcomes for millions of patients.

03Mar 25

Mankind Pharma Faces ₹112 Crore Tax Demand, Plans to Appeal

Mankind Pharma has received an additional tax demand of ₹112 crore from the Income Tax Department. The company believes the demand is not legally tenable and intends to appeal against the order. Mankind Pharma does not expect any material impact on its financial position or operations due to this development.

28Feb 25

Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal

Mankind Pharma has received an additional tax demand of ₹111.68 crore from the Income Tax Department for the Assessment Year 2021-22. The demand stems from adjustments under sections 80IC/80IE and disallowances under section 37(1) of the Income-tax Act. The company believes the demand is not tenable and plans to appeal, stating it has adequate grounds to support its case. Mankind Pharma does not expect any material impact on its financials or operations due to this order.

28Feb 25

Mankind Pharma's MSCI Weightage Increase and Subsidiary Merger Approval

Mankind Pharma's weightage in the MSCI India Standard Index is set to increase, potentially attracting $48 million inflow. The company has also received NCLT approval to merge three wholly-owned subsidiaries, aiming to streamline operations, optimize resources, and enhance competitive advantage. The merger's appointed date is April 1, 2024, with NCLT approval on February 25, 2025.

27Feb 25

NCLT Greenlights Mankind Pharma's Strategic Consolidation Move

The National Company Law Tribunal (NCLT) has approved the amalgamation of three wholly-owned subsidiaries with Mankind Pharma Limited, effective April 1, 2024. The merger aims to consolidate resources, enhance operational synergies, optimize costs, and improve financial management. This strategic move is expected to strengthen Mankind Pharma's position in the pharmaceutical industry without immediate impact on shareholders. The company's stock showed a marginal increase of 0.04% following the announcement.